Press Releases
Eyevensys Announces Executive Leadership Team Expansion 1920 1277 Eyevensys

Eyevensys Announces Executive Leadership Team Expansion

Gerald Cagle, Ph.D. named Chairman of the Board Francine Behar-Cohen, M.D., Ph.D. named Chief Innovation Officer Thierry Bordet, Ph.D. named Chief Scientific Officer Paris, France, and Fort Worth, Texas, United…

Eyevensys Closes $30M Series B Financing 1920 1281 Eyevensys

Eyevensys Closes $30M Series B Financing

Eyevensys announced today that it has completed a $30 million Series B financing. The round was led by Boehringer Ingelheim Venture Fund and included participation from existing investors Pontifax, Bpifrance,…

Eyevensys Presents Initial Data from Phase I/II, Non-Viral Gene Therapy for Ocular Diseases 1920 1281 Eyevensys

Eyevensys Presents Initial Data from Phase I/II, Non-Viral Gene Therapy for Ocular Diseases

Eyevensys this week presented results from part 1 of its phase I/II study for non-infectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual OIS@AAO conference on October 10,…

Eyevensys Appoints New Board Member, Gerald Cagle 1920 1280 Eyevensys

Eyevensys Appoints New Board Member, Gerald Cagle

Eyevensys today announced that Gerald (Jerry) Cagle, Ph.D., former Senior Vice President and Chief Scientific Officer at Alcon Laboratories has joined its Board  of Directors. Dr. Cagle is a highly…

Eyevensys Appoints Dr. Patricia Zilliox as Chief Executive Officer 1667 2500 Eyevensys

Eyevensys Appoints Dr. Patricia Zilliox as Chief Executive Officer

Paris (France), December 12th, 2017 – Eyevensys, a clinical stage biotech company developing non-viral gene therapies for ophthalmic diseases, today announced the appointment of Dr. Patricia Zilliox as CEO. Dr.…

Eyevensys Appoints Thierry Bordet Ph.D. as Pre-Clinical Director 1668 2500 Eyevensys

Eyevensys Appoints Thierry Bordet Ph.D. as Pre-Clinical Director

Paris (France), 13th September 2017 – Eyevensys, a clinical stage biotech company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enables the safe, local, sustained production…

Eyevensys Appoints Dr Ronald R. Buggage as Chief Medical Officer 2500 1667 Eyevensys

Eyevensys Appoints Dr Ronald R. Buggage as Chief Medical Officer

Paris (France), 4th September 2017 – Eyevensys, a clinical stage biotech company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enables the safe, local, sustained production…

Eyevensys Announces the First-in-Human Treatment with its GroundBreaking EyeCET ElectroTransfection Technology for Eye Diseases 2500 1667 Eyevensys

Eyevensys Announces the First-in-Human Treatment with its GroundBreaking EyeCET ElectroTransfection Technology for Eye Diseases

Eyevensys announces today that it has successfully treated the first patient in a first-in-human phase I/II trial of its lead candidate EYS606 for Non-Infectious Uveitis (NIU). The patient was treated…

Eyevensys Receives Approval from the UK Medicines and Healthcare products Regulatory Agency to advance its EyeCET platform into clinical development 2500 1668 Eyevensys

Eyevensys Receives Approval from the UK Medicines and Healthcare products Regulatory Agency to advance its EyeCET platform into clinical development

Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enables the safe, local, sustained production of therapeutic proteins in the eye to…

Eyevensys Receives Approval from the French Product Security Regulatory Agency ANSM to advance its EyeCET platform into clinical development 2500 1667 Eyevensys

Eyevensys Receives Approval from the French Product Security Regulatory Agency ANSM to advance its EyeCET platform into clinical development

Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enables the safe, local, sustained production of therapeutic proteins in the eye to…